Synovial Sarcoma: A Comparative Study of Immunohistochemical Markers (Bcl2 and CD99) versus Fluorescence In Situ Hybridization

  • Chandana G Department of Pathology, Dr. Patnam Mahendar Reddy Institute of Medical Sciences and Hospital, Chevella, RR district, Telangana, India
  • Triveni Bhopal Department of Pathology, Director of Medical Education, Hyderabad, Telangana, India
  • Vijaya Durga K Department of Pathology, Aira Diagnostics, Hyderabad, Telangana, India
  • Mahesh Kumar Usha Department of Pathology, Dr. Patnam Mahendar Reddy Institute of Medical Sciences and Hospital, Chevella, RR district, Telangana, India
  • Rajput S.A Kiran Singh Department of Pathology, Dr. Patnam Mahendar Reddy Institute of Medical Sciences and Hospital, Chevella, RR district, Telangana, India
DOI: https://doi.org/10.21276/apalm.3340
Keywords: Synovial sarcoma, Bcl2, CD99, Immunohistochemistry, Fluorescent in situ hybridization

Abstract

Background Synovial Sarcoma (SS) is a mesenchymal tumor, which displays a variable degree of epithelial differentiation including gland formation, and has a specific chromosomal translocation t(x;18)(p11;q11) that leads to the formation of an SS18-SSX fusion gene. The diagnostic gold standard for Synovial Sarcoma is the demonstration of the characteristic translocation between the SS18 (SYT) gene on chromosome 18 and one of the three SSX genes (SSX1, SSX2, or rarely SSX4) on chromosome X {t(x;18)(p11.2;q11.2)} [1, 2]. The use of these techniques is limited by many practical issues like cost and specialized equipment availability. Thus, in practice, the diagnosis of SS is usually based on histological examination and immunohistochemistry (IHC) [3, 4]. Our objective is to study the expression of Bcl2 and CD99 in Synovial Sarcoma and to compare the results with fluorescence in situ hybridization (FISH) to evaluate the sensitivity of Bcl2 and CD99 in the diagnosis of Synovial Sarcoma. Material and Methods Tissue was processed and microtomy was done. Hematoxylin and eosin (H&E) staining was performed. IHC was carried out on all sections using CD99, Bcl2, EMA, CK, and all other markers which aid in differentiating SS from its mimics. All the formalin-fixed paraffin-embedded (FFPE) tissue samples from 50 histologically diagnosed Synovial Sarcoma cases, which showed Bcl2 and CD99 positivity, were submitted for FISH.. Results Forty cases out of fifty histologically and Bcl2 & CD99 positive Synovial Sarcoma cases were positive for FISH, showing the t(x;18)(p11.2;q11.2) translocation. Conclusion Bcl2, CD99, Vimentin, EMA, and PCK are routinely used markers in the diagnosis of Synovial Sarcoma. It is found that Bcl2 and CD99 are highly sensitive markers in the initial diagnosis and management of Synovial Sarcoma in patients who cannot afford cytogenetic studies.

References

Chang CC, Shidham VB. Molecular genetics of pediatric soft tissue tumors: clinical application. J Mol Diagn. 2003;5(3):143-54.

Coindre JM, Pelmus M, Hostein I, Lussan C, Bui BN, Guillou L. Should molecular testing be required for diagnosing synovial sarcoma? A prospective study of 204 cases. Cancer. 2003;98(12):2700-7.

Sun B, Sun Y, Wang J, Zhao X, Zhang S, Liu Y, et al. The diagnostic value of SYT-SSX detection by reverse transcriptase-polymerase chain reaction and fluorescent in situ hybridization for synovial sarcoma: a review and prospective study of 255 cases. Cancer Sci. 2008;99(7):1355-61.

Amary MF, Berisha F, Bernardi FD, Herbert A, James M, Reis-Filho JS, et al. Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual colour FISH as diagnostic tools for synovial sarcoma. Mod Pathol. 2007;20(4):482-96.

Folpe AL, Schmidt RA, Chapman D, Gown AM. Poorly differentiated synovial sarcoma: immunohistochemical distinction from primitive neuroectodermal tumors and high grade malignant peripheral nerve sheath tumors. Am J Surg Pathol. 1998;22(6):673-82.

Pelmus M, Guillou L, Hostein I, Sierankowski G, Lussan C, Coindre JM. Monophasic fibrous and poorly differentiated synovial sarcoma immunohistochemical reassessment of 60 t(x;18)(SYT-SSX)-positive cases. Am J Surg Pathol. 2002;26(11):1434-40.

Ten Heuvel SE, Hoekstra HJ, Suurmeijer AJ, et al. Diagnostic accuracy of FISH and RT-PCR in 50 routinely processed synovial sarcomas. Appl Immunohistochem Mol Morphol. 2008;16(3):246-50.

He X, Xiong B, Zhou T, Lan T, Chen M, Chen H, et al. Diagnostic value of TLE1 for synovial sarcoma: immunohistochemical analyses of genetically confirmed synovial sarcoma and nonsynovial sarcomas. Int J Clin Exp Pathol. 2016;9(4):4339-50.

Deepthi B, Uppin SG, Challa S, Uppin MS, Paul TR, Prayaga AK, et al. Clinicopathological and immunohistochemical study of synovial sarcoma: a series of 42 cases from single institution. Saudi J Pathol Microbiol. 2018;3(7):201-10.

Dimitriadis E, Rontogianni D, Kyriazoglou A, Takou A, Frangia K, Pandis N, et al. Novel SYT-SSX fusion transcript variants in synovial sarcoma. Cancer Genet Cytogenet. 2009;195(1):54-8.

Fletcher CDM, Unni KK, Mertens F. World Health Organization classification of tumours of bones and soft tissue: tumors of uncertain differentiation. 4th ed. Lyon: IARC Press; 2013. p. 213-5.

Pretto D, Barco R, Rivera J, Neel N, Gustavson MD, Eid JE. The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene. 2006;25(26):3661-9.

Sabrazes J, Loubat E, de Grailly R, Magendie J. Synovial sarcoma. Gaz Hebd Sci Med Bordeaux. 1934;55:754-62.

Ladenstein R, Treuner J, Koscielniak E, et al. Synovial sarcoma of childhood and adolescence—report of the German CWS-81 study. Cancer. 1993;71:3647-55.

Meis-Kindblom JM, Stenman G, Kindblom LG. Differential diagnosis of small round cell tumors. Semin Diagn Pathol. 1996;13:213-20.

Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338:153-60.

Fligman I, Lonardo F, Jhanwar SC, Gerald WL, Woodruff J, Ladanyi M. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol. 1995;147:1592-9.

Antonescu CR, Kawai A, Leung DH, et al. Strong association of SYT-SSX fusion type and morphologic epithelial differentiation in synovial sarcoma. Diagn Mol Pathol. 2000;9:1-8.

Sucari SC, Vlok GW, Wagener DW, Zaharie D. Synovial sarcoma. S Afr J Radiol. 2014;18(2):704.

Kottu R, Prayaga AK. Synovial sarcoma with relevant immunohistochemistry and special emphasis on monophasic fibrous variant. J Cytol. 2010;27(2):47-50.

Published
26-05-2024
Issue
Vol 11 No 6 (2024)
Section
Original Article

Copyright (c) 2024 Chandana G, Triveni Bhopal, Vijaya Durga K, Mahesh Kumar Usha, Rajput S.A Kiran Singh

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).